<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cytokine treatment in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) aims to overcome the maturation defects of myeloid lineage cells associated with cytopenia and cellular dysfunction of mature cells </plain></SENT>
<SENT sid="1" pm="."><plain>Since phagocytes play a major role in host defense against microbial <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>, we investigated cytokine secretion and oxygen radical release (ORR) from peripheral blood monocytes (PBMC) in a total of 16 MDS patients, 12 patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA) and four patients with RA and excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Interleukin (IL-6), <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor alpha (TNF alpha), IL-1 beta, and IL-8 secretion from monocytes in response to <z:chebi fb="0" ids="16412">lipopolysaccharide</z:chebi> (LPS) was significantly reduced in the 12 patients with RA compared to 12 healthy controls, whereas no difference was seen in ORR </plain></SENT>
<SENT sid="3" pm="."><plain>We further assessed cytokine secretion from monocytes of 10 MDS patients before and after therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-3, or a combination therapy with GM-CSF and <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> (AraC) </plain></SENT>
<SENT sid="4" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> 10 patients, secretion of IL-1 beta, IL-6, and TNF alpha from PBMC increased after cytokine therapy, whereas IL-8 secretion increased only in five patients with GM-CSF or IL-3 therapy receiving a dosage &gt; or = 250 micrograms/m2 per day but decreased in <z:hpo ids='HP_0000001'>all</z:hpo> other patients </plain></SENT>
<SENT sid="5" pm="."><plain>ORR increased in <z:hpo ids='HP_0000001'>all</z:hpo> patients on either GM-CSF or IL-3 therapy </plain></SENT>
<SENT sid="6" pm="."><plain>These data indicate that the ability of monocytes to secrete secondary cytokines is impaired in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients but can be restored by in vivo administration of GM-CSF and IL-3 </plain></SENT>
</text></document>